🇪🇺 ACLIDINIUM in European Union

EMA authorised ACLIDINIUM on 19 November 2014

Marketing authorisation

EMA — authorised 19 November 2014

  • Application: EMEA/H/C/003969
  • Marketing authorisation holder: Covis Pharma Europe B.V.
  • Local brand name: Brimica Genuair
  • Indication: Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
  • Status: approved

Read official source →

ACLIDINIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ACLIDINIUM approved in European Union?

Yes. EMA authorised it on 19 November 2014.

Who is the marketing authorisation holder for ACLIDINIUM in European Union?

Covis Pharma Europe B.V. holds the EU marketing authorisation.